АДРЕНЕРГИЧЕСКИЕ СРЕДСТВА В КОРРЕКЦИИ ПОРТАЛЬНОЙ ГИПЕРТЕНЗИИ ПРИ ЦИРРОЗЕ ПЕЧЕНИ

  • Е. Л. Красавцев (E. L. Krasavtsev) Гомельский государственный медицинский университет https://orcid.org/0000-0001-7952-9385
  • А. В. Сенникова (A. V. Sennikova) Гомельский государственный медицинский университет https://orcid.org/0000-0002-7898-6530
Ключевые слова: цирроз печени, портальная гипертензия, полиморфизм, лечение

Аннотация

В обзоре приведены современные данные по проблеме профилактики кровотечения из варикозно-расширенных вен пищевода (ВРВП) с помощью различных адренергических средств. Освещены доказательства связи полиморфизмов гена b2-адренорецептора (ADRB2) с более значимым снижением градиента печеночно-венозного давления (ГПВД) в ответ на лечение неселективными бета-адреноблокаторами.

Литература


1. Sadovnikova II. Cirrozy pecheni. Voprosy jetiologii, patogeneza, kliniki, diagnostiki, lechenija. RMZh. Bolezni Organov Pishhevarenija. 2003;5(2):37-42. (Russian).


2. Kerefova ZSh, Pshegusova MH, Gubzhokova OZ. Medikosocialnye aspekty cirrozov pecheni virusnoj jetiologii. Simvol nauki. 2015;11-2:187-190. (Russian).


3. Pavlov ChS, Maevskaja MV, Kicenko EA, Kovtun VV, Ivashkin VT. Lekarstvennaja terapija portalnoj gipertenzii i ee oslozhnenij: analiz jeffektivnosti preparatov, primenjaemyh v klinicheskoj praktike, i obsuzhdenie perspektivnyh podhodov k lecheniju [Pharmacotherapy of portal hypertension and its complications: analysis of efficacy of preparations for clinical practice and discussion of promising methods of treatment]. Klinicheskaja medicina [Clinical medicine]. 2013;6:55-62. (Russian).


4. Schwabl Р, Laleman Р. Novel treatment options for portal hypertension. Gastroenterology Report. 2017;5(2):90-103. doi: 10.1093/gastro/gox011.


5. Reiberger T, Mandorfer M. Beta adrenergic blockade and decompensated cirrhosis. J. Hepatol. 2017;66(4):849-859. doi: 10.1016/j.jhep.2016.11.001.


6. Mandorfer M, Reiberger T. Beta blockers and cirrhosis, 2016. Dig. Liver Dis. 2017;49(1):3-10. doi: 10.1016/j. dld.2016.09.013.


7. de Franchis R, Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J. Hepatol. 2015;63(3):743-752. doi:10.1016/j.jhep. 2015.05.022.


8. Reiberger T, Payer BA, Schwabl P, Hayden H, Horvatits T, Jager B, Hummel T, Mitterhauser M, Trauner M, Fuhrmann V, Angermayr B, Peck-Radosavljevic M. Nebivolol treatment increases splanchnic blood flow and portal pressure in cirrhotic rats via modulation of nitric oxide signalling. Liver Int. 2013;33(4):561-568. doi: 10.1111/liv.12101.


9. Hemstreet BA. Evaluation of carvedilol for the treatment of portal hypertension. Pharmacotherapy. 2004;24(1):94-104. doi: 10.1592/phco.24.1.94.34805.


10. Reiberger T, Ulbrich G, Ferlitsch A, Payer BA, Schwabl P, Pinter M, Heinisch BB, Trauner M, Kramer L, Peck-Radosavljevic M. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut. 2013;62(11):1634-1641. doi: 10.1136/gutjnl-2012-304038.


11. Shah N, de Oca MM, Shah N, Dhar D, Jover-Cobos M, Davies AN, Mookerjee R, Jalan R. Treatment with an alpha 2a adrenoreceptor antagonist modulates hepatic inflammation, markedly reduces portal pressure, and improves arterial pressure and hepatic blood flow in cirrhotic rats. Gut. 2010;59(2):A25. doi: 10.1136/gut.2010.223362.61.


12. Jones H, Sharma V, Brandao da Silva AF, Davies NA, Macnaughtan J, Jalan R, Mookerjee RP. Noradrenaline potentiates portal hypertension through the alpha 2a adrenergic receptor - a target for therapy in portal hypertension. J. Hepatol. 2016;64(2):S446. doi: 10.1016/S0168-8278(16)00739-X.


13. Trebicka J, Hennenberg M, Probsting AS, Laleman W, Klein S, Granzow M, Nevens F, Zaagsma J, Heller J, Sauerbruch T. Role of beta3-adrenoceptors for intrahepatic resistance and portal hypertension in liver cirrhosis. Hepatology. 2009;50(6):1924-1935. doi: 10.1002/hep.23222.


14. Vasina V, Giannone F, Domenicali M, Latorre R, Berzigotti A, Caraceni P, Zoli M, de Ponti F, Bernardi M. Portal hypertension and liver cirrhosis in rats: effect of the beta3-adrenoceptor agonist SR58611A. Br. J. Pharmacol. 2012;167 (5):1137-1147. doi: 10.1111/j.1476-5381.2012.02074.x.


15. Parusov AI, Sychev DA, Loranskaja ID. Perspektivy personalizacii farmakoterapii portalnoj gipertenzii u bolnyh cirrozom pecheni [Pharmacotherapy personalization perspectives of portal hypertension in patients with liver cirrhosis].


16. Jeksperimentalnaja i klinicheskaja gastrojenterologija [Experimental and Clinical Gastroenterology]. 2018;150(2):142-148. (Russian).


17. Pascal JP, Cales P. Propranolol in the Primary Prevention of Upper Gastrointestinal Tract Haemorrhage in Patients with Cirrhosis of the Liver and Oesophageal Varices. Drugs. 1989;37(Suppl 2):52-61. doi: 10.2165/00003495- 198900372-00011.


18. Zhang F, Xu H, Chen M, Zhang M, Xiao J, Wang Y, He Q, Zhang W, Yin X, Zou X, Zhuge Y. Dose-dependent effect of propranolol on the hemodynamic response in cirrhotic patients with gastroesophageal varices. Eur. J. Gastroenterol. Hepatol. 2019;31(3):368-374. doi: 10.1097/MEG.0000000000001293.


19. Kong DR, Wang JG, Sun B, Wang MQ, Chen C, Yu FF, Xu JM. β-2 Adrenergic receptor gene polymorphism and response to propranolol in cirrhosis. World J. Gastroenterol. 2015;21(23):7191-7196. doi: 10.3748/wjg.v21.i23.7191.


20. Turnes J, Hernandez-Guerra M, Abraldes JG, Bellot P, Oliva R, Garcia-Pagan JC, Bosch J. Influence of beta-2 adrenergic receptor gene polymorphism on the hemodynamic response to propranolol in patients with cirrhosis. Hepatology. 2006;43(1):34-41. doi: 10.1002/hep.21000.


Просмотров аннотации: 66
Загрузок PDF: 37
Опубликован
2020-06-02